Intangible Assets (Details) - USD ($)		9 Months Ended	12 Months Ended
		Dec. 31, 2018	Mar. 31, 2018
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount		$ 7,713,001	$ 6,419,091
Additions			1,293,910
Accumulated Amortization		0	0
Net Book Value		$ 7,713,001	$ 7,713,001
Patent application costs [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life	[1]	0 years	0 years
Patent application costs, Gross Carrying Amount		$ 465,684	$ 371,774
Patent application costs, Additions			93,910
Accumulated Amortization
Net Book Value		465,684	465,684
ANDA acquisition costs [Member]
Finite-Lived Intangible Assets [Line Items]
Patent application costs, Gross Carrying Amount		7,247,317	6,047,317
Patent application costs, Additions			1,200,000
Accumulated Amortization
Net Book Value		$ 7,247,317	$ 7,247,317

[1] Patent application costs were incurred in relation to the Company's abuse deterrent opioid technology. Amortization of the patent costs will begin upon the issuance of marketing authorization by the FDA. Amortization will then be calculated on a straight-line basis through the expiry of the related patent(s).